Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 6/20 | 1.00 |
| ▸ | CTSV | O60911 | 1/20 | 0.68 |
| ▸ | CTSL | P07711 | 1/20 | 0.68 |
| ▸ | CA12 | O43570 | 2/20 | 0.67 |
| ▸ | CA9 | Q16790 | 2/20 | 0.67 |
| ▸ | FASN | P49327 | 1/20 | 0.60 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.60 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.60 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.60 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | TNKS | O95271 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | GPR3 | P46089 | 1/20 | 0.55 |
| ▸ | BLM | P54132 | 1/20 | 0.55 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6647395 | 0.87 | PARP1 (0.82) | PARP1CTSVCTSLCA12CA9 | |
| SCHEMBL30272741 | 0.85 | CTSV (0.79) | PARP1CTSVCTSLCA12CA9 | |
| SCHEMBL30272742 | 0.85 | CTSV (0.79) | PARP1CTSVCTSLCA12CA9 | |
| SCHEMBL30272743 | 0.85 | CTSV (0.79) | PARP1CTSVCTSLCA12CA9 | |
| SCHEMBL151534 | 0.85 | CTSV (0.79) | PARP1CTSVCTSLCA12CA9 | |
| SCHEMBL11365834 | 0.84 | PARP1 (0.72) | PARP1CTSVCTSLCA12CA9 | |
| SCHEMBL29540314 | 0.82 | GABRA1 (0.70) | PARP1CTSVCTSLCA12CA9 | |
| SCHEMBL155013 | 0.82 | GABRA1 (0.70) | PARP1CTSVCTSLCA12CA9 | |
| SCHEMBL7251935 | 0.81 | PARP1 (0.68) | PARP1CTSVCTSLCA12CA9 | |
| SCHEMBL21828651 | 0.81 | CTSV (1.00) | PARP1CTSVCTSLCA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11759524-B2 | Mitochondrially targeted PARP inhibitor, and uses thereof | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2023-09-19 | — | — | US | claimed |
| US-20210379191-A1 | Mitochondrially Targeted PARP Inhibitor, and Uses Thereof | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2021-12-09 | — | — | US | claimed |
| US-6358975-B1 | ADMINISTERING 3,4-DIHYDRO-5-(4-(1-PIPERIDINYL)-BUTOX)-1 (2H)-ISOQUINOLINONE, A SELECTIVE INHIBITOR OF POLY(ADP-RIBOSE) POLYMERASE FOR PROPHYLAXIS OF NEURAL TISSUE DAMAGE RESULTING FROM ISCHEMIA AND REPERFUSION INJURY OR NEURODEGENERATIVE | JOHNS HOPKINS UNIVERSITY | 2002-03-19 | — | — | US | claimed |
| US-5874444-A | CONTROLLING CELL AGING | GERON CORPORATION (US) | 1999-02-23 | — | — | US | claimed |
| WO-1998027975-A1 | POLY(ADP-RIBOSE) POLYMERASE INHIBITORS TO TREAT DISEASES ASSOCIATED WITH CELLULAR SENESCENCE | GERON CORPORATION (US) | 1998-07-02 | — | — | WO | claimed |
| EP-0638309-A1 | Substances inhibiting proteic adp ribosilation suitable to prevent the diabetes mellitus complications | ISTITUTO BIOCHIMICO ITALIANO GIOVANNI LORENZINI S.p.A. (IT) | 1995-02-15 | — | — | EP | claimed |
| EP-4419094-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF HYPERPROLIFERATIVE, INFLAMMATORY, AND IMMUNOLOGICAL DISEASES, AND INFECTIONS | Edison Oncology (US) | 2024-08-28 | — | — | EP | disclosed |
| US-20240156808-A1 | Compositions and methods to improve the therapeutic benefit of suboptimally chemical compounds and biological therapies including substituted camptothecins such as irinotecan and topotecan for the treatment of benign and neoplastic hyperproliferative disease conditions, infections, inflammatory and immunological diseases | EDISON ONCOLOGY (US) | 2024-05-16 | — | — | US | disclosed |
| EP-4297746-A2 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED COMPOUNDS AND THERAPIES FOR THE TREATMENT OF DISEASES | Edison Oncology (US) | 2024-01-03 | — | — | EP | disclosed |
| US-11759524-B2 | Mitochondrially targeted PARP inhibitor, and uses thereof | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2023-09-19 | — | — | US | disclosed |
| WO-2023069727-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF HYPERPROLIFERATIVE, INFLAMMATORY, AND IMMUNOLOGICAL DISEASES, AND INFECTIONS | EDISON ONCOLOGY (US) | 2023-04-27 | — | — | WO | disclosed |
| US-11446274-B2 | Use of dianhydrogalactitol or derivatives or analogs thereof for treatment of pediatric central nervous system malignancies | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2022-09-20 | — | — | US | disclosed |
| US-20210379191-A1 | Mitochondrially Targeted PARP Inhibitor, and Uses Thereof | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2021-12-09 | — | — | US | disclosed |
| US-6235748-B1 | CENTRAL NERVOUS SYSTEM DISORDERS; CARDIOVASCULAR DISORDERS | GUILFORD PHARMACEUTICALS INC. | 2001-05-22 | — | — | US | disclosed |
| WO-2001016136-A2 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASES | AGOURON PHARMACEUTICALS, INC. (US) | 2001-03-08 | — | — | WO | disclosed |
| WO-2000042040-A1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASES | AGOURON PHARMACEUTICALS, INC. (US) | 2000-07-20 | — | — | WO | disclosed |
| WO-1999008680-A1 | METHOD OF USING SELECTIVE PARP INHIBITORS TO PREVENT OR TREAT NEUROTOXICITY | THE JOHNS HOPKINS UNIVERSITY (US) | 1999-02-25 | — | — | WO | disclosed |
| US-5874444-A | CONTROLLING CELL AGING | GERON CORPORATION (US) | 1999-02-23 | — | — | US | disclosed |
| US-5589483-A | Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence | GERON CORPORATION (US) | 1996-12-31 | — | — | US | disclosed |
| EP-0638309-A1 | Substances inhibiting proteic adp ribosilation suitable to prevent the diabetes mellitus complications | ISTITUTO BIOCHIMICO ITALIANO GIOVANNI LORENZINI S.p.A. (IT) | 1995-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11446274-B2 | Use of dianhydrogalactitol or derivatives or analogs thereof for treatment of pediatric central nervous system malignancies | DCK, CDC7, DNMT1 | PARP1 418/4885CTSV 4719/4885CTSL 3550/4885 |
| US-11759524-B2 | Mitochondrially targeted PARP inhibitor, and uses thereof | PARP1, PARP2, PARP3 | PARP1 1/4885CTSV 3134/4885CTSL 2203/4885 |
| US-20240156808-A1 | Compositions and methods to improve the therapeutic benefit of suboptimally chemical compounds and biological therapies including substituted camptothecins such as irinotecan and topotecan for the treatment of benign and neoplastic hyperproliferative disease conditions, infections, inflammatory and immunological diseases | TOP2A, TOP2B, TOP1 | PARP1 92/4885CTSV 2705/4885CTSL 1533/4885 |
| US-20210379191-A1 | Mitochondrially Targeted PARP Inhibitor, and Uses Thereof | PARP1, PARP2, PARP3 | PARP1 1/4885CTSV 3134/4885CTSL 2203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.